Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

Leukemia Research

Volumn 36, Issue 9, 2012, Pages 1124-1127

  Quintás Cardama, Alfonso ^a   Kantarjian, Hagop ^a   Estrov, Zeev ^a   Borthakur, Gautam ^a   Cortes, Jorge ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Histone deacetylase inhibitor; JAK2; Myelofibrosis; Pracinostat; SB939

Indexed keywords

PRACINOSTAT;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MYELOID METAPLASIA; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BENZIMIDAZOLES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PRIMARY MYELOFIBROSIS; SPLEEN; SPLENOMEGALY; TREATMENT OUTCOME;

EID: 84864008019     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.03.003     Document Type: Article

References (20)

1. Spivak J.L. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004, 41:1-5.
2. Cervantes F., Dupriez B., Pereira A., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
3. James C., Ugo V., Le Couédic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
4. Lucet I.S., Fantino E., Styles M., et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006, 107:176-183.
5. V617F-mediated transformation. Proc Natl Acad Sci U S A 2005, 102:18962-18967.
6. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
7. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
8. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
9. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280:22788-22792.
10. Verstovsek S., Mesa R.A., Gotlib J., et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: results from COMFORT-I. Blood 2011, 118. (abstract 278).
11. Harrison C., Kiladjian J.J., Gisslinger H., et al. Ruxolitinib provides reductions in splenomegaly across subgroups: an analysis of spleen response in the COMFORT-II study. Blood 2011, 118. (abstract 279).
12. Quintas-Cardama A., Verstovsek S. Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. Cancer 2011, 118:870-877. 10.1002/cncr.26359.
13. Dawson M.A., Bannister A.J., Göttgens B., et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009, 461:819-822.
14. Herblot S., Steff A.M., Hugo P., Aplan P.D., Hoang T. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol 2000, 1:138-144.
15. Garcia-Manero G., Chuah C., Wilding G., et al. Phase I study of the oral histone deacetylase inhibitor SB939 in patients with advanced hematologic malignancies. Blood 2010, 116. (abstract 3292).
16. McClure R., Mai M., Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006, 20:168-171.
17. Tefferi A., Barosi G., Mesa R.A., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108:1497-1503.
18. V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010, 150:446-455.
19. DeAngelo D., Tefferi A., Fiskus W., et al. A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. Blood 2010, 116. (abstract 630).
20. V617F-driven disease. Blood 2011, 118. (abstract 798).